Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

By R. Ross, A. Paganini-Hill, Peggy Wan, M. Pike. Journal of the National Cancer Institute, 2000

686 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/b09aacac664196992a24db6022830cb15916155b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. humAn cArcinogens
2. Iarc Monographs
3. peRsonAl hAbIts
4. Rudolf Kaaks

In Oncology

1. H. Salehiniya
2. Zohre Momenimovahed
3. Rudolf Kaaks

Citations in the corpus

• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, background): “, 2007), one in those with an in-situ breast cancer after 5 or more years of use of estrogen-alone postmenopausal therapy (Ross et al., 2000), and one in those diagnosed with comedo carcinomas (Li et al.”
• Energy balance and cancer: the role of insulin and insulin-like growth factor-I (2001, background): “The oestrogen-plus-progestogen hypothesis may explain why post-menopausal hormone-replacement therapy with oestrogens plus progestogens appears to increase breast cancer risk more than the use of exogenous oestrogens alone (Ross et al. 2000; Schairer et al. 2000).”
• Epidemiological characteristics of and risk factors for breast cancer in the world (2019, background): “45).(73) In a cohort study, the researchers emphasized that the selection of progesterone in HRT should be based on the risk of developing breast cancer.”